Clinical trials are booming in Asian countries through recent years. The trials registered on clinicaltrials.gov shows that Asian countries comprise 15% of all trials since 2000 which ranks Asia on third position after North America and Europe and is still counting. This may be safely interpreted as Asian popularity is becoming more important in medical investigations and in global effort of fight against specific disease such as cancer. And research competence is getting stronger in Asia as well. The Korean Gynecologic Oncology Group (KGOG) was established in 2003 and has expanded its research capabilities blazingly fast. KGOG is actively engaged in number of trials with NRG oncology, keeps partnership with GCIG and more. One of the big collaboration with GOG was GOG 213 trial which was published in 2018. It was about whether to use bevacizumab after secondary cytoreduction in platinum- sensitive recurrent ovarian cancer and the participants from South Korea reached 43.7% out of 485 total enrollment. KGOG is currently involved in number of legacy GOG studies such as GOG 237, 278, 263, 265, RTOG 0724 and GCIG trials such as TACO, SHAPE. KGOG is recently continuing its collaboration with North Americans with NRG-005 and NRG-018 while actively proposing new concepts. KGOG also has active domestic protocols about early cervical cancer detection, novel approach to cervical cancer such as metformin, fertility-sparing in early endometrial cancer, and evaluation of HIPEC. Target therapies and immunologic drugs are also actively investigated by home-grown protocols. The bird's eye view of individual representative trials will be presented. KGOG is forging important trials within Asia as well. Durvalumab in recurrent ovarian clear cell cancer (MOCCA trial), upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer (SUNNY trial), opting out adjuvant chemotherapy in early ovarian cancer (JGOG 3020) are a few examples of collaboration currently on-going among Asian countries. Asia is unique in ethnicity and different in constitution from other regions hence results from previous trials performed mostly in western countries should be carefully vetted and interpreted as such. And it is yet another reason clinical trials in Asia are poised to increase. As Asia is contributing in every aspect globally, now is the time that Asians should come together in fight against gynecologic cancer.